Eisai and Biogen Launch Alzheimer's Drug Leqembi in South Korea
• Eisai and Biogen have launched Leqembi in South Korea for adults with mild cognitive impairment or early Alzheimer's disease.
• Leqembi targets amyloid-beta aggregates, reducing plaques in the brain and slowing the progression of Alzheimer's disease.
• Clinical trials demonstrated Leqembi reduced the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score, delaying disease progression.
• Eisai Korea is also seeking approval for a subcutaneous autoinjector to allow for convenient weekly self-administration of Leqembi.
© Copyright 2025. All Rights Reserved by MedPath